Pfizer acquires Vicuron Pharmaceuticals

Adjust font size:

Increase font size Decrease font size

Pfizer acquires Vicuron Pharmaceuticals

Pfizer, the world’s largest pharmaceutical manufacturer, announced that it will acquire Vicuron Pharmaceuticals, a biopharmaceutical company focused on developing anti-infection drugs, for $1.9 billion in cash.

Vicuron has two products currently under review at the US Food and Drug Administration: anidulafungin for fungal infections, and dalbavancin for skin and soft-tissue infections.

In 1992, Pfizer released the antifungal treatment Diflucan, followed by the launch of Vfend, another antifungal, in 2002. Pfizer currently sells Zithromax, the largest selling antibiotic in the world, and Zyvox, a oxazolidinone targeted at more serious infections.

“By acquiring Vicuron, we can help bring two very important new medicines to patients around the world,” said Hank McKinnell, chairman and chief executive officer of Pfizer. “This transaction builds on Pfizer’s extensive experience in anti-infectives and demonstrates our commitment to strengthen and broaden our pharmaceutical business through strategic product acquisitions.”

Completion of this transaction is subject to regulatory approval, Vicuron shareholder's approval and other customary closing conditions. The acquisition is expected to close during the third quarter of this year.

Comments on this story

no comments yet...

click here to add a comment

You must be registered & logged in to add comments
Please register

already have an account and just want to login?

email address
password
remember me
 

Related Content

Boeing Celebrates the Premiere of the 787 Dreamliner
EVERETT, Wash., July 08, 2007 -- Today, Boeing...
more…